Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer

National Cancer Center, Korea36 enrolled

Overview

Proton alone therapy is performed -\> 5 times a week, 7200 cGy / 15 fractions for 3 weeks total

This clinical trial is a prospective, single-organ, phase II clinical trial to evaluate the efficacy of curative proton therapy for pulmonary metastasis of colon cancer diagnosed histologically as adenocarcinoma. Patients who meet the selection criteria should be selected, signed for consent, and treated 5 times a week for 7200 cGy / 15 fractions alone for 3 weeks.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Colorectal Cancer

Interventions

curative proton therapyRADIATION

Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Histologically diagnosed colon adenocarcinoma in primary or metastatic lesions.. 2. If there is no other remote metastasis other than lung, or if there is, control is possible 3. If there are less than 2 lung metastatic lesions 4. If they refuse lung surgery or surgery is inappropriate (medically unsuitable for surgery due to surgery refusal, diabetes mellitus, high blood pressure, pulmonary disease, heart disease, etc., repeated surgery, poor systematic function, short disease-free period, etc.) Exclusion Criteria: 1. Other histologic cancer other than adenocarcinoma of the colorectal 2. Colorectal cancer without primary lesion resection 3. If there is another remote metastasis and is not completely resected or regulated 4. If the patient has experience of other invasive cancer diagnosis within 5 years of colorectal cancer diagnosis 5. Pregnancy and women under lactation

Locations (1)

National Cancer Center Korea

Goyang-si, Gyeonggi-do, South Korea

RECRUITING

Outcomes

Primary Outcomes

3-year local control ratio of the treated lung area

The primary goal of this study is the 3-year local control rate of pulmonary lesions treated with proton therapy. It is judged that the local control rate is improved when the pulmonary metastases of colorectal cancer using conventional X-ray is assumed to have 3-year local control rate of 60% and the 3-year local control rate of proton therapy is set to 80% or more

Time frame: up to 3 years

Secondary Outcomes

3-year survival rate of treated patients

To evaluate whether high doses of proton therapy can replace conventional surgical resection. From date of initiation of proton therapy until the date of documented date of death from any cause, assessed up to 3 years

Time frame: documented data of death, up to 3 years

3-year disease-free survival rate of treated patients

To evaluate whether high doses of proton therapy can replace conventional surgical resection. From date of initiation of proton therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.

Time frame: documented date of progression or death, up to 3 years

Central Contacts

Dae Yong Kim, M.D.

CONTACT

82-31-920-1721 radiopia@ncc.re.kr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.